

Supplementary Online Content

Friedmann PD, Wilson D, de Gijzel D, et al. Mobile telemedicine for treating chronic hepatitis C among rural people who inject drugs: a randomized clinical trial. *JAMA Netw Open*. 2026;9(1):e2555125. doi:10.1001/jamanetworkopen.2025.55125

eTable 1. Schedule of Participant Payments

eTable 2. Baseline Characteristics Comparing Randomized Participants With and Without Follow-Up Data, Rural Northern New England, 2022 to 2024

eTable 3. Viral Clearance at 12-Week Follow-Up by Study Condition, Initiation, and Completion of Direct-Acting Antiviral (DAA) Treatment, Rural Northern New England, 2022 to 2024

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Schedule of participant payments.	
Tested negative for HCV antibody at Visit T0, or otherwise excluded.	\$10
Tested positive for HCV antibody, had a venous blood draw performed and completed enrollment at Visit T0.	\$20
Attended Visit T1, ineligible for randomization. Excluded, received laboratory results and appropriate referrals.	\$10
Attended Visit T1, eligible for randomization and treatment, completed the baseline ACASI interview.	\$20
Attended brief week 4 check-in visit	\$20
Attended “end-of-treatment visit” (week 8 or 12 after treatment initiation Visit T1, or week 16 if treatment not initiated)	\$40
Attended 12 week follow-up (week 12 after “end-of-treatment” or 28 weeks after Visit T1 if treatment not initiated)	\$40
Attended 24 week follow-up (week 24 after “end-of-treatment” or 40 weeks after Visit T1 if treatment not initiated)	\$40
Attended 36 week follow-up (week 36 after “end-of-treatment” or 52 weeks after Visit T1 if treatment not initiated)	\$60
Referred a potentially eligible participant who completed the enrollment (T0) visit, whether or not they were eventually eligible for randomization and treatment.	\$5

eTable 2. Baseline characteristics comparing randomized participants with and without follow-up data, rural northern New England, 2022 to 2024

	Has any follow-up data?	
	No	Yes
All randomized participants	31 (20.8)	119 (79.3)
Site, N (%)		
Cheshire County (Keene), NH	14 (27.5)	37 (72.6)
Windham County (Brattleboro), VT	10 (12.1)	73 (88.0)
Bennington County (Bennington), VT	7 (43.85)	9 (56.3)
Age, mean (std deviation)	35.3 (6.42)	38.8 (8.40)
Gender, N (%)		
Male	24 (23.3)	79 (76.7)
Female	5 (11.4)	39 (88.6)
Other		1 (100)
Missing	2 (100)	
Race, N (%)		
Asian, Pacific Islander		1 (100)
Black		2 (100)
Mixed race	2 (25.0)	6 (75.0)
White	27 (20.2)	107 (79.9)
Other*		3 (100)
Missing	2 (100)	
Hispanic, N (%)		
Yes	2 (25.0)	6 (75.0)
No	27 (19.6)	111 (80.4)
Don't know		2 (100)
Missing	2 (100)	
Education, N (%)		
Less than high school	9 (20.9)	34 (79.1)
High school diploma or GED	12 (17.1)	58 (82.9)
Some college	6 (23.1)	20 (76.9)
Associates degree, trade or technical	1 (20.0)	4 (80.0)
College degree or more	1 (33.3)	2 (66.7)
Missing	2 (100)	1 (100)
Health insurance coverage, N (%)		
Yes	27 (19.2)	114 (80.9)
No	1 (25.0)	3 (75.0)
Don't know	1 (33.3)	2 (66.7)
Missing	2 (100)	
Unhoused in past 6 months, N (%)		
Yes	22 (21.0)	83 (79.0)
No	6 (14.3)	36 (85.7)
Missing/Refused	3 (100)	

Ever overdosed, N (%)		
Yes	22 (21.6)	80 (78.4)
No	7 (15.2)	39 (84.8)
Missing	2 (100)	
Injected within 30 days of baseline, N (%)		
Yes	16 (16.5)	81 (83.5)
No	13 (25.5)	38 (74.5)
Missing	2 (100)	
MOUD within 30 days of baseline, N (%)		
Yes	13 (23.6)	42 (76.4)
No	15 (16.9)	74 (83.2)
Don't know		3 (100)
Missing	3 (100)	
Reported shared syringes/equipment within 30 days of baseline, N (%)		
Yes	7 (24.1)	22 (75.9)
No	21 (17.8)	97 (82.2)
Missing	3 (100)	
Any opioid use within 30 days of baseline, N (%)		
Yes	18 (17.1)	87 (82.9)
No	11 (25.6)	32 (74.4)
Missing	2 (100)	

Abbreviations. EUC: Enhanced Usual Care; MTC: Mobile Telemedicine HCV Care; MOUD: Medication for Opioid Use Disorder

*In the Other category, two individuals reported “Hebrew” and one “Italian.”

eTable 3. Viral clearance at 12-week follow-up* by study condition, initiation, and completion of direct-acting antiviral (DAA) treatment, rural northern New England, 2022 to 2024

	Row Total	Viral Clearance*		
		Yes	No	Missing/Not Obtained
Mobile HCV Telemedicine Care [MTC], n (%)	75	28 (37.3)	25 (33.3)	24 (32.0)
Did not initiate DAA treatment	13	1 (7.7)	10 (76.9)	2 (15.4)
Initiated DAA treatment	43	27 (62.8)	12 (27.9)	4 (9.3)
Initiated but did not complete DAA treatment	9	4 (44.4)	4 (44.4)	1 (11.1)
Completed DAA treatment	34	23 (67.7)	8 (25.5)	3 (8.8)
Missing initiation or completion status	19	0	1 (5.3)	18 (94.7)
Enhanced Usual Care [EUC], n (%)	75	14 (18.7)	45 (60.0)	16 (21.3)
Did not initiate DAA treatment	42	1 (2.4)	38 (90.5)	3 (7.1)
Initiated DAA treatment	20	13 (65.0)	6 (30.0)	1 (5.0)
Initiated but did not complete DAA treatment	5	2 (40.0)	3 (60.0)	0
Completed DAA treatment	15	11 (73.3)	3 (20.0)	1 (6.7)
Missing initiation or completion status	13	0	1	12

*Viral clearance was assessed as negative HCV RNA at the 12-week follow-up after treatment completion (i.e., sustained viral response at 12 weeks [SVR12] among treated participants) or week 28 after randomization (Visit T1) among participants who did not initiate treatment.